EndoBind detects endogenous protein-protein interactions in real time.
Autorzy:
Bill A; Novartis Institute for Biochemical Research, Oncology, Cambridge, MA, USA. . Espinola S; Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA. Guthy D; Novartis Institute for Biochemical Research, Oncology, Basel, Switzerland. Haling JR; Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA.; Mirati Therapeutics, Inc., Research, San Diego, CA, USA. Lanter M; Novartis Institute for Biochemical Research, Oncology, Basel, Switzerland. Lu M; Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA. Marelli A; Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA. Mendiola A; Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA. Miraglia L; Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA. Taylor BL; Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA. Vargas L; Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA. OrthAP; Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA. King FJ; Genomics Institute of the Novartis Research Foundation, Assay Development and High Throughput Screening, San Diego, CA, USA. .
Pokaż więcej
Źródło:
Communications biology [Commun Biol] 2021 Sep 15; Vol. 4 (1), pp. 1085. Date of Electronic Publication: 2021 Sep 15.
Co-regulatory networks of human serum proteins link genetics to disease.
Autorzy:
Emilsson V; Icelandic Heart Association, Holtasmari 1, IS-201 Kopavogur, Iceland. .; Faculty of Pharmacology, University of Iceland, 101 Reykjavik, Iceland. Ilkov M; Icelandic Heart Association, Holtasmari 1, IS-201 Kopavogur, Iceland. Lamb JR; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA. . Finkel N; Novartis Institutes for Biomedical Research, 22 Windsor Street, Cambridge, MA 02139, USA. Gudmundsson EF; Icelandic Heart Association, Holtasmari 1, IS-201 Kopavogur, Iceland. Pitts R; Novartis Institutes for Biomedical Research, 22 Windsor Street, Cambridge, MA 02139, USA. Hoover H; Novartis Institutes for Biomedical Research, 22 Windsor Street, Cambridge, MA 02139, USA. Gudmundsdottir V; Icelandic Heart Association, Holtasmari 1, IS-201 Kopavogur, Iceland. Horman SR; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA. Aspelund T; Icelandic Heart Association, Holtasmari 1, IS-201 Kopavogur, Iceland.; Centre of Public Health Sciences, University of Iceland, 101 Reykjavik, Iceland. Shu L; Department of Integrative Biology and Physiology, University of California, Los Angeles CA, USA. Trifonov V; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA. Sigurdsson S; Icelandic Heart Association, Holtasmari 1, IS-201 Kopavogur, Iceland. Manolescu A; School of Science and Engineering, Mentavegur 1, IS-101, Reykjavik University, 101 Reykjavik, Iceland. Zhu J; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Olafsson Ö; Icelandic Heart Association, Holtasmari 1, IS-201 Kopavogur, Iceland. Jakobsdottir J; Icelandic Heart Association, Holtasmari 1, IS-201 Kopavogur, Iceland. Lesley SA; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA. To J; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA. Zhang J; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA. Harris TB; Laboratory of Epidemiology and Population Sciences, Intramural Research Program, National Institute on Aging, Bethesda, MD 20892-9205, USA. Launer LJ; Laboratory of Epidemiology and Population Sciences, Intramural Research Program, National Institute on Aging, Bethesda, MD 20892-9205, USA. Zhang B; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Eiriksdottir G; Icelandic Heart Association, Holtasmari 1, IS-201 Kopavogur, Iceland. Yang X; Department of Integrative Biology and Physiology, University of California, Los Angeles CA, USA. OrthAP; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA. Jennings LL; Novartis Institutes for Biomedical Research, 22 Windsor Street, Cambridge, MA 02139, USA. Gudnason V; Icelandic Heart Association, Holtasmari 1, IS-201 Kopavogur, Iceland. .; Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2018 Aug 24; Vol. 361 (6404), pp. 769-773. Date of Electronic Publication: 2018 Aug 02.
Typ publikacji:
Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
High Throughput Random Mutagenesis and Single Molecule Real Time Sequencing of the Muscle Nicotinic Acetylcholine Receptor.
Autorzy:
Groot-Kormelink PJ; Musculoskeletal Disease Area, Novartis Institutes for BioMedical Research, Basel, Switzerland. Ferrand S; Center for Proteomic Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland. Kelley N; Analytical Sciences and Imaging, Novartis Institutes for BioMedical Research, Basel, Switzerland. Bill A; Center for Proteomic Chemistry, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States of America. Freuler F; Center for Proteomic Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland. Imbert PE; Center for Proteomic Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland. Marelli A; Genomics Institute of the Novartis Research Foundation, Novartis Institutes for BioMedical Research, San Diego, California, United States of America. Gerwin N; Musculoskeletal Disease Area, Novartis Institutes for BioMedical Research, Basel, Switzerland. Sivilotti LG; Department of Neuroscience, Physiology and Pharmacology, University College London, London, United Kingdom. Miraglia L; Genomics Institute of the Novartis Research Foundation, Novartis Institutes for BioMedical Research, San Diego, California, United States of America. OrthAP; Genomics Institute of the Novartis Research Foundation, Novartis Institutes for BioMedical Research, San Diego, California, United States of America. Oakeley EJ; Analytical Sciences and Imaging, Novartis Institutes for BioMedical Research, Basel, Switzerland. Schopfer U; Center for Proteomic Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland. Siehler S; Center for Proteomic Chemistry, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2016 Sep 20; Vol. 11 (9), pp. e0163129. Date of Electronic Publication: 2016 Sep 20 (Print Publication: 2016).
High throughput mutagenesis for identification of residues regulating human prostacyclin (hIP) receptor expression and function.
Autorzy:
Bill A; Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America. Rosethorne EM; Respiratory Disease Area, Novartis Institutes for Biomedical Research, Horsham, United Kingdom. Kent TC; Respiratory Disease Area, Novartis Institutes for Biomedical Research, Horsham, United Kingdom. Fawcett L; Respiratory Disease Area, Novartis Institutes for Biomedical Research, Horsham, United Kingdom. Burchell L; Respiratory Disease Area, Novartis Institutes for Biomedical Research, Horsham, United Kingdom. van Diepen MT; Respiratory Disease Area, Novartis Institutes for Biomedical Research, Horsham, United Kingdom. Marelli A; Infectious Diseases, Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America. Batalov S; Infectious Diseases, Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America. Miraglia L; Infectious Diseases, Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America. OrthAP; Infectious Diseases, Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America. Renaud NA; Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America. Charlton SJ; Respiratory Disease Area, Novartis Institutes for Biomedical Research, Horsham, United Kingdom. Gosling M; Respiratory Disease Area, Novartis Institutes for Biomedical Research, Horsham, United Kingdom. Gaither LA; Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States of America. Groot-Kormelink PJ; Respiratory Disease Area, Novartis Institutes for Biomedical Research, Horsham, United Kingdom; Musculoskeletal Disease Area, Novartis Institutes for Biomedical Research, Basel, Switzerland.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2014 Jun 02; Vol. 9 (6), pp. e97973. Date of Electronic Publication: 2014 Jun 02 (Print Publication: 2014).
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
